Literature DB >> 35876924

Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells.

Yuta Kimura1, Ryouichi Tsunedomi2, Kiyoshi Yoshimura3, Satoshi Matsukuma1, Yoshitaro Shindo1, Hiroto Matsui1, Yukio Tokumitsu1, Shin Yoshida1, Michihisa Iida1, Nobuaki Suzuki1, Shigeru Takeda1, Tatsuya Ioka4, Shoichi Hazama5, Hiroaki Nagano1.   

Abstract

BACKGROUND: Poor prognosis in liver cancer is due to its high frequency of intrahepatic metastasis. Cancer stem-like cells (CSLCs), which possess the properties of stemness, tumor initiation capability, and resistance to therapy, also exhibit metastatic potential. Immune surveillance plays an important role in the accomplishment of metastasis. Herein, the property of immune evasion in CSLCs was investigated.
METHODS: Sphere cells were induced as CSLCs using a sphere induction medium containing neural survival factor-1. The expression of genes involved in immune evasion was determined using RNA-sequencing for sphere and parental cells followed by validation using flow cytometric analysis and ELISA. Susceptibility to natural killer (NK) cell-mediated cytotoxicity was examined by a chromium release assay. A xenograft model using BALB/c nu/nu mice was used to assess tumor growth. Gene set enrichment analysis was performed for interpreting RNA sequencing.
RESULTS: The cell surface expressions of PD-L1, PD-L2, and CEACAM1 were upregulated and those of ULBP1 and MICA/MICB were downregulated in SK-sphere, CSLCs derived from SK-HEP-1, compared with that in parental cells. Levels of soluble MICA were elevated in conditioned medium from SK-sphere. Expression of HLA class I was not downregulated in SK-sphere. The susceptibilities to NK cell-mediated killing and secreted perforin were significantly lower in both CSLCs derived from SK-HEP-1 and HLE than in parental cells. Tumors formed upon inoculation of SK-sphere in immunodeficient mice harboring NK cells were larger than those formed upon inoculation of parental cells.
CONCLUSION: Human hepatoma cell line-derived CSLCs may possess immune evasion properties, especially from NK cell-mediated immunity.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35876924     DOI: 10.1245/s10434-022-12220-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  49 in total

Review 1.  Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Kazuhiko Sakamoto; Hiroaki Nagano
Journal:  Hepatol Res       Date:  2017-08-20       Impact factor: 4.288

2.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

Review 3.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Jessica Zucman-Rossi; Eli Pikarsky; Bruno Sangro; Myron Schwartz; Morris Sherman; Gregory Gores
Journal:  Nat Rev Dis Primers       Date:  2016-04-14       Impact factor: 52.329

Review 4.  Hepatocellular carcinoma: current management and perspectives for the future.

Authors:  Nuh N Rahbari; Arianeb Mehrabi; Nathan M Mollberg; Sascha A Müller; Moritz Koch; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Authors:  Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2019-09-06       Impact factor: 4.288

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.

Authors:  Parissa Tabrizian; Ghalib Jibara; Brian Shrager; Myron Schwartz; Sasan Roayaie
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

Review 9.  Current topics in the surgical treatments for hepatocellular carcinoma.

Authors:  Daisuke Ban; Toshiro Ogura; Keiichi Akahoshi; Minoru Tanabe
Journal:  Ann Gastroenterol Surg       Date:  2018-02-28

10.  Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi-institutional study by the Kyushu Study Group of Liver Surgery.

Authors:  Yo-Ichi Yamashita; Ken Shirabe; Toru Beppu; Susumu Eguchi; Atsushi Nanashima; Masayuki Ohta; Shinichi Ueno; Kazuhiro Kondo; Kenji Kitahara; Masayuki Shiraishi; Yuko Takami; Tomoaki Noritomi; Kohji Okamoto; Yoshito Ogura; Hideo Baba; Hikaru Fujioka
Journal:  Ann Gastroenterol Surg       Date:  2017-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.